Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

XCUR Exicure, Inc.

Post-Market Trading 03-25 17:25:52 EDT

13.27

-0.30

-2.21%

盘后13.54

+0.27+2.03%

16:05 EDT

High13.49	Low12.89	Vol6.73K
Open12.92	D1 Closing13.57	Amplitude4.40%
Mkt Cap83.84M	Tradable Cap60.91M	Total Shares6.32M
T/O89.25K	T/O Rate0.15%	Tradable Shares4.59M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Invest in Global Markets with Tiger Brokers!

Open App

{"stockData":{"symbol":"XCUR","market":"US","secType":"STK","nameCN":"Exicure, Inc.","latestPrice":13.27,"timestamp":1742932800000,"preClose":13.57,"halted":0,"volume":6734,"hourTrading":{"tag":"盘后","latestPrice":13.54,"preClose":13.27,"latestTime":"16:05 EDT","volume":2,"amount":27.08,"timestamp":1742933110467},"delay":0,"floatShares":4589700,"shares":6317771,"eps":-2.19642,"marketStatus":"Post-Market Trading","change":-0.3,"latestTime":"03-25 17:25:52 EDT","open":12.92,"high":13.485,"low":12.8886,"amount":89252.6681,"amplitude":0.04395,"askPrice":14.23,"askSize":22,"bidPrice":13.15,"bidSize":1,"shortable":3,"etf":0,"ttmEps":-2.19642,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1742947200000},"marketStatusCode":4,"adr":0,"exchange":"NASDAQ","adjPreClose":13.57,"preHourTrading":{"tag":"盘前","latestPrice":13.5,"preClose":13.57,"latestTime":"09:19 EDT","volume":237,"amount":3201.095721,"timestamp":1742908796843},"postHourTrading":{"tag":"盘后","latestPrice":13.54,"preClose":13.27,"latestTime":"16:05 EDT","volume":2,"amount":27.08,"timestamp":1742933110467},"volumeRatio":0.215685},"requestUrl":"/m/hq/s/XCUR","defaultTab":"news","newsList":[{"id":"2520319199","title":"Exicure FY24 EPS $(4.75) Up From $(10.55) YoY; Revenue $500K","url":"https://stock-news.laohu8.com/highlight/detail?id=2520319199","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520319199?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:04","pubTimestamp":1742328298,"startTime":"0","endTime":"0","summary":"Exicure FY24 EPS $(4.75) Up From $(10.55) YoY; Revenue $500K","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/03/44384714/exicure-fy24-eps-4-75-up-from-10-55-yoy-revenue-500k","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"Exicure FY24 EPS $(4.75) Up From $(10.55) YoY; Revenue $500K","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR"],"gpt_icon":0},{"id":"2520385931","title":"Exicure, Inc. Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520385931","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520385931?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:01","pubTimestamp":1742328060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUA1RKN02:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2520313139","title":"Exicure Inc - Cash May Not Be Sufficient to Fund Operations; Doubts Ability to Continue as Going Concern","url":"https://stock-news.laohu8.com/highlight/detail?id=2520313139","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520313139?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:01","pubTimestamp":1742328060,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250318:nTUA1RKN02:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2520931393","title":"Press Release: Exicure, Inc. Reports Full Year 2024 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2520931393","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2520931393?lang=en_us&edition=full_marsco","pubTime":"2025-03-19 04:01","pubTimestamp":1742328060,"startTime":"0","endTime":"0","summary":"Exicure, Inc.  has historically been an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. In September 2022, the Company announced a significant reduction in force, suspension of preclinical activities and halting of all research and development, and that the Company was exploring strategic alternatives to maximize stockholder value. We continue to engage in a broader exploration of strategic alternatives. This effort involves exploring growth through transactions with potential partners that see opportunity in joining an existing, publicly-traded organization.Cash Position: Cash and cash equivalents were $12.5 million as of December 31, 2024, as compared to $0.8 million as of December 31, 2023. Our current liquidity may not be sufficient to fund operations for the next 12 months. Additional financing will be needed to fund our ongoing operations and exploration of strategic alternatives and pursue any a","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2519826680","title":"Exicure Gets Patent in Australia for Potential Cancer Treatment Combination","url":"https://stock-news.laohu8.com/highlight/detail?id=2519826680","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519826680?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 16:20","pubTimestamp":1741940413,"startTime":"0","endTime":"0","summary":"Exicure  said late Thursday it received a patent in Australia covering its combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx.The patent supports the company's ongoing phase 2 clinical trial assessing the combination of GPC-100 and propranolol to treat multiple myeloma, a cancer of plasma cells.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XKO.AU","XAO.AU","BK4139","XJO.AU","XCUR"],"gpt_icon":0},{"id":"2519864583","title":"Exicure, Inc. Announces Issuance of New Patent in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2519864583","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519864583?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 04:45","pubTimestamp":1741898701,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250313:nFWN3PW0U6:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2519861560","title":"Exicure, Inc. (Nasdaq: XCUR) Announces Issuance of New Patent in Australia","url":"https://stock-news.laohu8.com/highlight/detail?id=2519861560","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2519861560?lang=en_us&edition=full_marsco","pubTime":"2025-03-14 04:08","pubTimestamp":1741896480,"startTime":"0","endTime":"0","summary":"CHICAGO, March 13, 2025----Exicure, Inc.  today announced that the Australian Patent Office has issued Patent No. 2018388302, titled \"GPCR Heteromer Inhibitors and Uses Thereof.\" This patent covers the company’s innovative combination approach to cancer treatment, specifically targeting CXCR4 and GPCRx.The newly granted patent supports Exicure’s ongoing Phase 2 clinical trial , which evaluates the combination of GPC-100 and propranolol in multiple myeloma patients. This method aims to improve hematopoietic stem cell mobilization by co-targeting CXCR4 and ADRB2, thereby enhancing the efficacy of CXCR4 inhibitors like GPC-100.\"This issuance reinforces the exclusivity of our lead clinical program,\" said Andy Yoo, CEO of Exicure, Inc. \"By co-targeting CXCR4 and ADRB2, we can significantly enhance the potency of CXCR4 inhibitors like GPC-100. This opens new possibilities for these inhibitors to become more effective therapies, and our well-devised patent portfolio ensures strong intellectua","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/exicure-inc-nasdaq-xcur-announces-200800965.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["BK4588","USAW.SI","LU2210149790.SGD","NVIW.SI","NQmain","IE00B3QW5Z07.USD","QLD","LU2210150020.SGD","BK4112","LU2095319765.USD","TSYW.SI","NDAQ",".IXIC","IE00B64PRP62.GBP","BK4585","MNQmain","SQQQ","PSQ","USJW.SI","TQQQ","XCUR","BK4139","IE00BGHQF748.EUR","QID","IE00BKPKM429.USD"],"gpt_icon":1},{"id":"2516739966","title":"Top Premarket Gainers","url":"https://stock-news.laohu8.com/highlight/detail?id=2516739966","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2516739966?lang=en_us&edition=full_marsco","pubTime":"2025-03-04 20:36","pubTimestamp":1741091764,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) shares surged 14% pre-bell Tuesday, extending Monday's rally.RxSight (RXST) shares advanced 15% following a 5% drop in the previous session.Okta (OKTA) shares increased 14%, a day after","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0516422366.SGD","LU2286300806.USD","SG9999002406.SGD","SG9999002679.SGD","LU0979878070.USD","LU1242518857.USD","LU0251143029.SGD","LU0345776255.USD","SG9999002604.SGD","SG9999006266.SGD","ASTH","BK4528","BK4116","LU0516422440.USD","LU0516422952.EUR","BK4503","BK4539","BK4548","BK4560","LU0516423174.USD","LU0737861269.HKD","LU2045819591.USD","BK4585","LU0048573645.USD","SG9999013486.USD","OKTA","SG9999002620.SGD","SG9999013460.SGD","BK4581","SGXZ58947870.SGD","LU1770036033.HKD","LU2125910500.SGD","XCUR","BK4535","BK4588","BK4139","LU0345775950.USD","BK4566","LU0499858602.USD","LU0499858438.USD","LU0532188223.SGD","BK4551","BK4198","LU1242518931.SGD","IE0034224299.USD","SG9999002414.USD","SE","RXST","SG9999005177.SGD","LU0210637038.USD"],"gpt_icon":1},{"id":"2505402066","title":"Exicure Acquires GPCR's California Subsidiary, Enters Into Licensing Agreement","url":"https://stock-news.laohu8.com/highlight/detail?id=2505402066","media":"MT Newswires Live","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505402066?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 16:52","pubTimestamp":1737622351,"startTime":"0","endTime":"0","summary":"Exicure  said late Wednesday it has agreed to acquire all shares of GPCR Therapeutics USA, a subsidiary of GPCR Therapeutics, a Korean corporation.In connection with the deal, Exicure and GPCR made a licensing and collaboration agreement to further develop and commercialize certain GPCR technologies, the company said.Financial terms were not disclosed.Under the agreement, Exicure is to pay GPCR milestone payments upon reaching specific milestone events relating to clinical trials, marketing authorizations, and net sales, as well as a recurring royalty payment based on at least 10% of net sales, the company said.Shares of Exicure were up more than 46% in Wednesday's after-hours activity.Price: 15.21, Change: +4.84, Percent Change: +46.67","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["XCUR","BK4007","GPCR","BK4139","BK4599"],"gpt_icon":1},{"id":"2505701720","title":"BRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2505701720","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505701720?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 05:53","pubTimestamp":1737582837,"startTime":"0","endTime":"0","summary":"BRIEF-Exicure, Inc. Announces Purchase Agreement With Gpcr Therapeutics Inc.Exicure Inc XCUR.O:EXICURE, INC. ANNOUNCES PURCHASE AGREEMENT WITH GPCR THERAPEUTICS INC.EXICURE INC: ACQUIRED FROM GPCR ALL","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA5GH44K:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2505706822","title":"Exicure announces purchase agreement with GPCR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2505706822","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505706822?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 05:05","pubTimestamp":1737579939,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) “announced that on January 19, 2025, Exicure Inc. entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corp...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-announces-purchase-agreement-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-announces-purchase-agreement-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["GPCR","BK4599","BK4139","BK4007","XCUR"],"gpt_icon":0},{"id":"2505705258","title":"Exicure Inc: Acquired From Gpcr All of Issued and Outstanding Equity Securities of Gpcr Therapeutics USA Inc","url":"https://stock-news.laohu8.com/highlight/detail?id=2505705258","media":"THOMSON REUTERS","labels":["merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505705258?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 05:01","pubTimestamp":1737579660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA5GH44K:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"merge","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2505705247","title":"Exicure - Co, Gpcr Enter License and Collaboration Agreement to Further Develop, Commercialize Gpcr’s Techs Related to Certain Ip, Patents","url":"https://stock-news.laohu8.com/highlight/detail?id=2505705247","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505705247?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 05:01","pubTimestamp":1737579660,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250122:nTUA5GH44K:3","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["XCUR","BK4139"],"gpt_icon":0},{"id":"2505705211","title":"Press Release: Exicure, Inc. Announces Purchase Agreement with GPCR Therapeutics Inc.","url":"https://stock-news.laohu8.com/highlight/detail?id=2505705211","media":"Dow Jones","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2505705211?lang=en_us&edition=full_marsco","pubTime":"2025-01-23 05:01","pubTimestamp":1737579660,"startTime":"0","endTime":"0","summary":"Exicure, Inc. , today announced that on January 19, 2025, Exicure Inc.  entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation , pursuant to which the Company acquired from GPCR all of the issued and outstanding equity securities of GPCR Therapeutics USA Inc., a California corporation . The transactions contemplated under the Share Purchase Agreement closed concurrently with execution. GPCR USA was, until immediately prior to closing under the Share Purchase Agreement, a wholly owned subsidiary of GPCR.In December of last year, GPCR USA presented results at the American Society of Hematology conference, indicating that inhibiting both CXCR4 and ADRB2  resulted in a more than tenfold increase in the anti-cancer efficacy of the AML chemotherapy drug cytarabine. Notably, they reported high response rates and excellent safety profiles in patients receiving the new blood cancer drug daratumumab. Dr. Caderelli stated, \"After completing patient treatment, we","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CTO","BK4599","XCUR","BK4007","BK4139","HSCT","GPCR","BK4160"],"gpt_icon":1},{"id":"2504816720","title":"Exicure Inc trading resumes","url":"https://stock-news.laohu8.com/highlight/detail?id=2504816720","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504816720?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 23:00","pubTimestamp":1737126059,"startTime":"0","endTime":"0","summary":"09:58 EST Exicure (XCUR) Inc trading resumes Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-inc-trading-resumes-7?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-inc-trading-resumes-7?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2504162986","title":"Exicure Inc trading halted, volatility trading pause","url":"https://stock-news.laohu8.com/highlight/detail?id=2504162986","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2504162986?lang=en_us&edition=full_marsco","pubTime":"2025-01-17 22:55","pubTimestamp":1737125737,"startTime":"0","endTime":"0","summary":"09:53 EST Exicure (XCUR) Inc trading halted, volatility trading pause Published first on TheFly – the ultimate source for real-time, market-moving ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-inc-trading-halted-volatility-trading-pause-7?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-inc-trading-halted-volatility-trading-pause-7?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","XCUR"],"gpt_icon":0},{"id":"2494383980","title":"Sector Update: Health Care Stocks Mixed Pre-Bell Friday","url":"https://stock-news.laohu8.com/highlight/detail?id=2494383980","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494383980?lang=en_us&edition=full_marsco","pubTime":"2024-12-27 22:05","pubTimestamp":1735308314,"startTime":"0","endTime":"0","summary":"Health care stocks were mixed pre-bell Friday as the iShares Biotechnology ETF (IBB) was 0.1% higher and the Health Care Select Sector SPDR Fund (XLV) was down 0.2% recently.UnitedHealth Group (UNH) a","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["LU0149725797.USD","LU0310800379.SGD","LU0211328371.USD","LU2361044865.SGD","TAK","IE0002270589.USD","LU0077335932.USD","SGXZ51526630.SGD","XCUR","LU1066051811.HKD","IE00B19Z9505.USD","LU2089984988.USD","IE00B4JS1V06.HKD","IE00BFSS8Q28.SGD","LU0289739699.SGD","LU0820561818.USD","IE00B4R5TH58.HKD","UNH","LU1814569148.SGD","LU0553294199.USD","LU0158827948.USD","LU2347655156.SGD","LU1069347547.HKD","AMED","LU0251132253.USD","LU2357305700.SGD","LU2361045086.USD","LU0079474960.USD","IE0004445015.USD","IE00B1XK9C88.USD","LU0417517546.SGD","LU1267930730.SGD","LU1074936037.SGD","IBB","LU0672654240.SGD","LU0345770308.USD","LU1854103824.USD","SG9999014898.SGD","LU0354030511.USD","LU1778281490.HKD","LU1003077747.HKD","LU0320765059.SGD","LU1934455277.USD","LU1496350502.SGD","LU0198837287.USD","SG9999001176.SGD","IE00BN29S564.USD","XLV","LU2111349929.HKD","LU2211815571.USD"],"gpt_icon":1},{"id":"2494387996","title":"Exicure to Acquire GPCR Therapeutics' US Unit","url":"https://stock-news.laohu8.com/highlight/detail?id=2494387996","media":"MT Newswires Live","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494387996?lang=en_us&edition=full_marsco","pubTime":"2024-12-27 16:51","pubTimestamp":1735289493,"startTime":"0","endTime":"0","summary":"Exicure (XCUR) said late Thursday it signed a memorandum of understanding with GPCR Therapeutics for the acquisition of the South Korean company's US subsidiary, GPCR USA, to advance its growth as a c","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4007","GPCR","BK4599","BK4139","XCUR"],"gpt_icon":0},{"id":"2494843517","title":"Exicure signs MOU with GPCR Therapeutics","url":"https://stock-news.laohu8.com/highlight/detail?id=2494843517","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494843517?lang=en_us&edition=full_marsco","pubTime":"2024-12-27 09:25","pubTimestamp":1735262745,"startTime":"0","endTime":"0","summary":"The company states: “Exicure (XCUR) has announced the signing of a Memorandum of Understanding, MOU, with GPCR Therapeutics on December 24, 2024, a...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/exicure-signs-mou-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/exicure-signs-mou-with-gpcr-therapeutics?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4599","XCUR","GPCR","BK4139","BK4007"],"gpt_icon":0},{"id":"2494810036","title":"BRIEF-Exicure Partners With GPCR Therapeutics To Fuel New Growth In Biotech","url":"https://stock-news.laohu8.com/highlight/detail?id=2494810036","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2494810036?lang=en_us&edition=full_marsco","pubTime":"2024-12-27 09:12","pubTimestamp":1735261928,"startTime":"0","endTime":"0","summary":"BRIEF-Exicure Partners With GPCR Therapeutics To Fuel New Growth In BiotechDec 26 (Reuters) - Exicure Inc XCUR.O:EXICURE, INC. PARTNERS WITH GPCR THERAPEUTICS TO FUEL NEW GROWTH IN BIOTECHSource text: ID:nBw1xXcfdaFurther company coverage: XCUR.O ((reuters.briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241227:nFWN3NR03N:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","XCUR"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.exicuretx.com","stockEarnings":[{"period":"1week","weight":0.0446},{"period":"1month","weight":0.5871},{"period":"3month","weight":-0.2101},{"period":"6month","weight":2.7077},{"period":"1year","weight":3.3175},{"period":"ytd","weight":-0.0073}],"compareEarnings":[{"period":"1week","weight":0.0122},{"period":"1month","weight":-0.0431},{"period":"3month","weight":-0.0453},{"period":"6month","weight":0.0071},{"period":"1year","weight":0.1014},{"period":"ytd","weight":-0.0205}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Exicure, Inc. does not have significant operations. previously, the company focused on developing of nucleic acid therapies targeting ribonucleic acid against validated targets. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.","yearOnYearQuotes":[{"month":1,"riseRate":0.285714,"avgChangeRate":-0.021962},{"month":2,"riseRate":0.428571,"avgChangeRate":-0.034743},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.05246},{"month":4,"riseRate":0.5,"avgChangeRate":0.033364},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.019668},{"month":6,"riseRate":0.285714,"avgChangeRate":-0.007326},{"month":7,"riseRate":0.142857,"avgChangeRate":-0.061979},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.041199},{"month":9,"riseRate":0.285714,"avgChangeRate":0.003932},{"month":10,"riseRate":0.142857,"avgChangeRate":-0.08481},{"month":11,"riseRate":0.571429,"avgChangeRate":1.147671},{"month":12,"riseRate":0.428571,"avgChangeRate":-0.124719}],"exchange":"NASDAQ","name":"Exicure, Inc.","nameEN":"Exicure, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.32.1","shortVersion":"4.32.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Exicure, Inc.,XCUR,Exicure, Inc.股票,Exicure, Inc.股票老虎,Exicure, Inc.股票老虎国际,Exicure, Inc.行情,Exicure, Inc.股票行情,Exicure, Inc.股价,Exicure, Inc.股市,Exicure, Inc.股票价格,Exicure, Inc.股票交易,Exicure, Inc.股票购买,Exicure, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Exicure, Inc.(XCUR),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Exicure, Inc.(XCUR) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}